SpyGlass Pharma: Buy Rating Reiterated as Late-Stage Glaucoma Pipeline Advances; $37 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Yi Chen reiterated a Buy rating on SpyGlass Pharma with a $37 price target, citing advancing late-stage glaucoma pipelines and strong finances. Phase 3 BIM-IOL trials are on track for 2027 enrollment completion, with key data expected in late 2026. The upcoming first-in-human BIM-DRS trial offers potential for lifetime treatment. Supported by sufficient cash reserves through 2028 and DCF valuation, the rating stands despite inherent clinical and regulatory risks.
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on SpyGlass Pharma today and set a price target of $37.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Yi Chen has given his Buy rating due to a combination of factors, primarily centered on SpyGlass Pharma’s advancing clinical programs and solid financial position. The company’s Phase 3 BIM-IOL trials are progressing as planned, with enrollment expected to complete in 2027 and meaningful four-year follow-up data from the first-in-human study anticipated in late 2026, supporting confidence in long-term efficacy and safety.
Yi Chen’s optimism is further underpinned by the upcoming first-in-human BIM-DRS trial, which could broaden SpyGlass’s reach across glaucoma and ocular hypertension patients while enabling repeated treatment over a lifetime. Together with a cash balance that appears sufficient to fund operations through at least 2028, and a DCF-based valuation that supports a $37 price target, these elements collectively justify maintaining a Buy rating despite typical clinical, regulatory, commercial, and dilution risks.